-
Posted by
Two Blokes Jun 17 -
Filed in
Stock
-
4 views
AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost revenue, driving robust year-over-year growth and demonstrating AbbVie's R&D strength. AbbVie's diversified pipeline, strategic partnerships, and expansion into oncology and neuroscience provide multiple growth drivers beyond immunology.
